Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 7/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900510 | 0.87 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL1985123 | 0.83 | MAOB (0.46) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL6592049 | 0.83 | MAOB (0.50) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL56658 | 0.83 | MAOB (0.46) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL2074306 | 0.83 | MAOB (0.46) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL10720650 | 0.83 | MAOB (0.46) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL6087084 | 0.83 | MAOB (0.43) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL6591192 | 0.81 | MAOB (0.44) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL10363838 | 0.80 | MAOB (0.43) | MAOBMAOAGRM5METNPC1 | |
| SCHEMBL10363956 | 0.80 | MAOB (0.43) | MAOBMAOAGRM5METNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-119136619-A | Perovskite solar cell and chemical induction surface reconstruction preparation method | 陕西师范大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-114641477-B | Compounds having inhibitory activity on glucosylceramide synthase or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-03-12 | — | — | CN | disclosed |
| US-20230002380-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-114641477-A | Novel compound having inhibitory activity against glucose ceramide synthase or pharmaceutically acceptable salt thereof, method for preparing same, and pharmaceutical composition comprising same | 柳韩洋行 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021096241-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | WO | disclosed |
| EP-2714697-B1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-9303037-B2 | Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| US-9079919-B2 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-5776699-A | MEASURING GENE EXPRESSION | ALLERGAN, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998025875-A1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | MAOB 3060/4885MAOA 3414/4885GRM5 2821/4885 |
| US-20230002380-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GBA1, GBA2, GALC | MAOB 2090/4885MAOA 2295/4885GRM5 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.